Login to Your Account



Financings Roundup

Vasopharm Gets $7M to Prep for Pivotal Brain Injury Trial

By Cormac Sheridan
Staff Writer

Monday, June 24, 2013
Vasopharm GmbH raised €5 million (US$6.5 million) in new investment to fund preparations for a Phase III trial of VAS203, an allosteric inhibitor of nitric oxide (NO) synthase in development for treating traumatic brain injury (TBI).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription